Thrivent Financial for Lutherans
PTGX icon

Thrivent Financial for Lutherans’s Protagonist Therapeutics PTGX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.87M Buy
39,697
+472
+1% +$49.3K 0.01% 1002
2026
Q1 		$4.13M Sell
39,225
-1,155
-3% -$102K 0.01% 1003
2025
Q4 		$3.53M Sell
40,380
-1,808
-4% -$148K 0.01% 1100
2025
Q3 		$2.8M Sell
42,188
-3,388
-7% -$193K 0.01% 1135
2025
Q2 		$2.52M Buy
45,576
+1,800
+4% +$86.4K 0.01% 1198
2025
Q1 		$2.12M Sell
43,776
-2,290
-5% -$96K ﹤0.01% 1260
2024
Q4 		$1.78M Sell
46,066
-191
-0.4% -$8.33K ﹤0.01% 1517
2024
Q3 		$2.08M Buy
+46,257
New +$1.87M ﹤0.01% 1410
2023
Q3 		– Sell
-73,381
Closed -$2.03M – 2484
2023
Q2 		$2.03M Sell
73,381
-27,612
-27% -$691K ﹤0.01% 1325
2023
Q1 		$2.32M Hold
100,993
– – 0.01% 1202
2022
Q4 		$1.1M Hold
100,993
– – ﹤0.01% 1667
2022
Q3 		$852K Buy
+100,993
New +$956K ﹤0.01% 1784

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Thrivent Financial for Lutherans's PTGX Position: Q2 2026 in Review

Thrivent Financial for Lutherans increased its Protagonist Therapeutics (PTGX) stake by 1.2% in Q2 2026, buying an estimated $49.3K and bringing the position to 39,697 shares worth $4.87M. The position accounts for 0.01% of the portfolio, ranked #1002.

Thrivent Financial for Lutherans first reported a position in PTGX in Q3 2022 and has held it in 12 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Thrivent Financial for Lutherans held 39,697 shares of Protagonist Therapeutics worth $4.87M as of Q2 2026.
  • Thrivent Financial for Lutherans bought 472 Protagonist Therapeutics shares in Q2 2026, an estimated $49.3K.
  • Protagonist Therapeutics made up 0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #1002 holding.
  • Thrivent Financial for Lutherans first reported a position in Protagonist Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.